J. Gabrilove

J. Gabrilove, 2002, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan

J. Gabrilove, D. Rifkin, G. Brunner, 1991, The Journal of cell biology.

Long-term culture of human bone marrow stromal cells in the presence of basic fibroblast growth factor.

J. Gabrilove, D. Rifkin, E. Wilson, 1990, Growth factors.

Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

M. Grever, J. Byrd, T. Kipps, 2010 .

Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis

Urvish K. Patel, J. Gabrilove, H. Sacks, 2020, BMJ Evidence-Based Medicine.

Fluoride: A toxic or therapeutic agent in the treatment of osteoporosis?

J. Gabrilove, J. Aaseth, M. Shimshi, 2004 .

Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

T. Miller, T. Kipps, J. Gabrilove, 2016, Haematologica.

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

J. Gabrilove, A. Shih, J. Mascarenhas, 2021, HemaSphere.

Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study

J. Herman, J. Gabrilove, P. Greenberg, 2016, British journal of haematology.

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine‐treated patients with myelodysplastic syndromes

J. Gabrilove, P. Greenberg, M. Tallman, 2014, British journal of haematology.

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

J. Gabrilove, P. Greenberg, M. Tallman, 2014, British journal of haematology.

Stem cell factor and basic fibroblast growth factor are synergistic in augmenting committed myeloid progenitor cell growth.

J. Gabrilove, E. Wilson, Z. Rahman, 1994, Blood.

A path forward: Global health, telemedicine, and hematology

J. Gabrilove, A. Binder, 2016, American journal of hematology.

The development of granulocyte colony-stimulating factor in its various clinical applications.

J. Gabrilove, 1992, Blood.

Anemia and the elderly: clinical considerations.

J. Gabrilove, 2005, Best practice & research. Clinical haematology.

The acute metabolic effects of tumor necrosis factor administration in humans.

J. Gabrilove, R. Warren, M. Brennan, 1987, Archives of surgery.

Granulocyte colony stimulating factor (G-CSF): biology and clinical status.

J. Gabrilove, A. Jakubowski, 1996, Cancer biotherapy & radiopharmaceuticals.

Phase I Clinical Studies of Tumor Necrosis Factor in Patients with Advanced Cancer

J. Gabrilove, E. Casper, P. Chapman, 1990 .

Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.

J. Gabrilove, E. Casper, P. Chapman, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Specific expression of the human cellular fps/fes-encoded protein NCP92 in normal and leukemic myeloid cells.

J. Gabrilove, H. Hanafusa, J. Tam, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Signaling pathways in lymphoma: pathogenesis and therapeutic targets.

J. Myklebust, J. Gabrilove, D. McFarland, 2013, Future oncology.

Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.

J. Gabrilove, H. Scher, C. Sternberg, 1988, The Journal of clinical investigation.

Granulocyte colony-stimulating factor: preclinical and clinical studies.

J. Gabrilove, A. Jakubowski, 1989, Hematology/oncology clinics of North America.

Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer.

J. Gabrilove, E. Casper, H. Oettgen, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of recombinant human tumor necrosis factor α, recombinant human γ-interferon, and prostaglandin E on colony formation of human hematopoietic progenitor cells stimulated by natural human pluripotent colony-stimulating factor, pluripoietin α, and recombinant erythropoietin in serum-free cultur

J. Gabrilove, K. Welte, H. Broxmeyer, 1986 .

MATURATIONAL FACTORS IN MYELOID LEUKEMIA1

J. Gabrilove, K. Welte, M. Moore, 1985 .

Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.

J. Gabrilove, R. Motzer, H. Scher, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates

J. Gabrilove, T. Boone, K. Welte, 1987, The Journal of experimental medicine.

Interleukin-1: biological effects in human hematopoiesis.

J. Gabrilove, J. Crown, A. Jakubowski, 1993, Leukemia & lymphoma.

Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy.

G. Demetri, J. Gabrilove, J. Glaspy, 2002, Clinical breast cancer.

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

J. Herman, J. Gabrilove, A. Melnick, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical benefits of epoetin alfa therapy in patients with lung cancer.

G. Demetri, J. Gabrilove, J. Crawford, 2002, Clinical lung cancer.

Activities of four purified growth factors on highly enriched human hematopoietic progenitor cells.

J. Gabrilove, K. Welte, B. Clarkson, 1987, Blood.

An analysis of current neutropenia therapies, including pegfilgrastim.

J. Gabrilove, 2006, Clinical cornerstone.

Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia.

J. Gabrilove, B. Clarkson, M. Moore, 1989, The New England journal of medicine.

Overview: erythropoiesis, anemia, and the impact of erythropoietin.

J. Gabrilove, 2000, Seminars in hematology.

Pluripoietin alpha: a second human hematopoietic colony-stimulating factor produced by the human bladder carcinoma cell line 5637.

J. Gabrilove, R. Mertelsmann, K. Welte, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.

J. Gabrilove, P. Greenberg, H. Kantarjian, 2010, Blood.

Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

J. Gabrilove, P. Greenberg, M. Tallman, 2010 .

Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine

J. Gabrilove, P. Greenberg, H. Kantarjian, 2008 .

Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

J. Gabrilove, H. Kantarjian, S. Eckert, 2008 .

A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study

J. Gabrilove, P. Greenberg, M. Tallman, 2010 .

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Francisco Cervantes, Thomas Fischer, Alois Gratwohl, 2006, The New England journal of medicine.

Impact of rituximab on COVID-19 outcomes

J. Gabrilove, G. Lancman, Hannah Levavi, 2021, Annals of Hematology.

Myeloid leukemic cell differentiation induced by human postendotoxin serum and vitamin analogues.

J. Gabrilove, M. Moore, A. Sheridan, 1983, Haematology and blood transfusion.

Clinical applications of granulocyte colony stimulating factor (G-CSF).

J. Gabrilove, 1992, Growth factors.

Biological activities of recombinant human granulocyte colony stimulating factor (rhG-CSF) and tumor necrosis factor: in vivo and in vitro analysis.

J. Gabrilove, K. Welte, M. Moore, 1987, Haematology and blood transfusion.

Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.

J. Gabrilove, R. Mertelsmann, K. Welte, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Treatment of chronic neutropenia associated with large granular lymphocytosis with cyclosporine a and filgrastim

J. Gabrilove, A. Jakubowski, E. Winton, 1995, American journal of hematology.

Effects of recombinant human granulocyte-colony stimulating factor on hematopoietic reconstitution after autologous bone marrow transplantation in primates.

J. Gabrilove, K. Welte, M. Bonilla, 1987, Transplantation proceedings.

Human pluripotent hemopoietic colony stimulating factor: activities on human and murine cells.

J. Gabrilove, R. Mertelsmann, K. Welte, 1986, Immunobiology.

High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses.

J. Gabrilove, D. Niedzwiecki, D. Mintzer, 1987, Cancer treatment reports.

Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells.

J. Gabrilove, D. Rifkin, Rifkin, 1993, Blood.

Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells

J. Gabrilove, R. Mertelsmann, K. Welte, 1985, The Journal of experimental medicine.

Constitutive production of leukemia differentiation, colony-stimulating, erythroid burst-promoting, and pluripoietic factors by a human hepatoma cell line: characterization of the leukemia differentiation factor.

J. Gabrilove, K. Welte, L. Lu, 1985, Blood.

Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.

J. Gabrilove, M. Andreeff, J. Kolitz, 1989, Seminars in oncology.

Fine needle aspiration of osteitis fibrosa cystica

P. Unger, J. Gabrilove, C. Watson, 1985, Diagnostic cytopathology.

Biological activities of a human pluripotent hemopoietic colony-stimulating factor.

J. Gabrilove, R. Mertelsmann, K. Welte, 1985, Haematology and blood transfusion.

Purification to apparent homogeneity and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.

J. Gabrilove, R. Mertelsmann, K. Welte, 1985, Haematology and blood transfusion.

Infection with human T-cell leukemia virus type I in patients with leukemia.

J. Gabrilove, D. Scheinberg, B. Clarkson, 1988, The New England journal of medicine.

Thalidomide alone or in combination with fludarbabine are effective treatments for patients with fludarabine-relapsed and refractory CLL

J. Leonard, J. Gabrilove, R. Furman, 2005 .

Use of CSF-G in Acute Nonlymphocytic Leukemia

J. Gabrilove, A. Jakubowski, 1993 .

Antitumor activity of actinonin in vitro and in vivo.

J. Gabrilove, D. Scheinberg, L. Lai, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Growth factors in human cancer.

J. Gabrilove, J. Mendelsohn, 1990, Current opinion in oncology.

Ibrutinib dose modifications in the management of CLL

J. Gabrilove, R. Pinotti, Camille Hardy-Abeloos, 2020, Journal of Hematology & Oncology.

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.

J. Gabrilove, H. Scher, C. Sternberg, 1988, The New England journal of medicine.

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.

J. Gabrilove, M. Maris, H. Kantarjian, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL

J. Gabrilove, A. Steinberg, G. Lancman, 2018, International journal of hematology-oncology and stem cell research.

Ultrastructure of leydig cell paracrystalline inclusions, possibly related to reinke crystals, in the normal human testis

J. Gabrilove, J. Churg, A. Sohval, 1973, Zeitschrift für Zellforschung und Mikroskopische Anatomie.

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

Janice Gabrilove, Glenn Heller, J. Gabrilove, 1991 .

Gynecomastia and Bilateral Testicular Masses Secondary to Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency)

J. Gabrilove, H. Yeh, C. Watlington, 1991 .

Down-regulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells

J. Gabrilove, S. Waxman, Y. Jing, 2012, Leukemia.

Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.

P. Pandolfi, Z. G. Wang, J. Gabrilove, 1998, Blood.

Hematologic malignancies: an opportunity for targeted drug therapy.

J. Gabrilove, 2001, The oncologist.

Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells

J. Gabrilove, S. Waxman, Y. Jing, 2015, Clinical Cancer Research.

Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.

J. Gabrilove, S. Heimfeld, S. Nimer, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.

J. Gabrilove, M. Andreeff, J. Kolitz, 1991, Blood.

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

J. Gabrilove, J. Sparano, S. Ely, 2011, Cancer.

Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805

M. Grever, J. Byrd, J. Gabrilove, 2005, Clinical Cancer Research.

Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells

J. Gabrilove, S. Waxman, P. Gong, 2018, Molecular Cancer Therapeutics.

Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.

J. Gabrilove, J. Bertino, P. Hamlin, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis.

J. Gabrilove, K. Welte, M. Abboud, 1989, The New England journal of medicine.

Distinct differentiation-inducing activities of gamma-interferon and cytokine factors acting on the human promyelocytic leukemia cell line HL-60.

J. Gabrilove, K. Welte, P. Ralph, 1985, Cancer research.

Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.

J. Gabrilove, A. Ho, S. Nimer, 1997, Blood.

Granulocyte colony stimulating factor for mucositis during post-operative radiotherapy.

J. Gabrilove, 2006, Cancer journal.

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

E. Winer, J. Gabrilove, C. Cleeland, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID‐19

J. Gabrilove, K. Sigel, D. Tremblay, 2020, British journal of haematology.

Serum granulocyte colony-stimulating factor levels are not increased in patients with autoimmune neutropenia of infancy.

J. Gabrilove, K. Welte, J. Bussel, 2000, The Journal of pediatrics.

Ultrasonography of adrenal masses: unusual manifestations.

J. Gabrilove, B. Wolf, H. Yeh, 1978, Radiology.

Signaling pathways in lymphoma: pathogenesis and therapeutic

J. Myklebust, J. Gabrilove, D. McFarland, 2013 .

Ultrasonography of adrenal masses: usual features.

J. Gabrilove, B. Wolf, H. Yeh, 1978, Radiology.

Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide

P. Pandolfi, S. Soignet, P. Maslak, 2001 .

Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines.

P. Pandolfi, J. Gabrilove, R. Warrell, 1997, Blood.

Effects of Recombinant Human Tumor Necrosis Factor a, Recombinant Human 7-Interferon, and Prostaglandin E on Colony Formation of Human Hematopoietic Progenitor Cells Stimulated by Natural Human Pluripotent Colonystimulating Factor, Pluripoietin a, and Recombinant Erythropoietin in Serum-free Culture

J. Gabrilove, R. Hoffman, H. Broxmeyer, 2006 .

Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.

M. Grever, J. Byrd, T. Kipps, 2015, Leukemia research.

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

T. Miller, T. Kipps, J. Gabrilove, 2013 .

Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).

Juswinder Singh, T. Kipps, J. Gabrilove, 2012 .

Cancer therapy. New strategies and treatment modalities for optimizing patient outcomes.

J. Gabrilove, Janice Gabrilove, 2001, Seminars in hematology.

A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma

J. Gabrilove, P. Chapman, R. Mertelsmann, 1988, Investigational New Drugs.

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes

J. Gabrilove, R. Paquette, M. Sekeres, 2008, British journal of haematology.

Introduction and overview of hematopoietic growth factors.

J. Gabrilove, 1989, Seminars in hematology (Print).

A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium

J. Gabrilove, V. Najfeld, A. Verma, 2008 .

Cancer Incidence in World Trade Center Rescue and Recovery Workers, 2001–2008

J. Gabrilove, P. Boffetta, P. Landrigan, 2013, Environmental health perspectives.

Basic fibroblast growth factor counteracts the suppressive effect of transforming growth factor-beta 1 on human myeloid progenitor cells.

G. Wong, J. Gabrilove, S. Kojima, 1993, Blood.

Basic fibroblast growth factor counteracts the suppressive effect of transforming growth factor-beta 1 on human myeloid progenitor cells

G. Wong, J. Gabrilove, S. Kojima, 1993 .

Modulation of leukemic cell growth by tumor necrosis factor: action and expression in myeloid leukemia.

J. Gabrilove, M. Moore, M. Steffen, 1992, Leukemia.

Prospective cohort study of the circadian rhythm pattern in allogeneic sibling donors undergoing standard granulocyte colony-stimulating factor mobilization

J. Gabrilove, J. Godbold, P. Frenette, 2013, Stem Cell Research & Therapy.

Phase I Trial of Intravenous and Intraperitoneal Administration of Granulocyte‐Macrophage Colony‐Stimulting Factor

J. Gabrilove, T. Boone, J. Crown, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Persistent gynecomastia resulting from scalp inunction of estradiol: a model for persistent gynecomastia.

J. Gabrilove, M. Luria, 1978, Archives of dermatology.

Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).

J. Leonard, J. Gabrilove, S. Ely, 2005 .

Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy‐induced anemia

E. Perez, J. Gabrilove, C. Cleeland, 2007, Cancer.

Intraoperative acute tumor lysis syndrome during laparoscopic splenectomy preceded by splenic artery embolization.

J. Gabrilove, A. Leibowitz, D. Labow, 2007, Surgical laparoscopy, endoscopy & percutaneous techniques.

A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndrome.

J. Gabrilove, R. Paquette, M. Sekeres, 2005 .

Ethacrynic Acid and a Derivative Enhance Apoptosis in Arsenic Trioxide–Treated Myeloid Leukemia and Lymphoma Cells: The Role of Glutathione S-Transferase P1-1

Janice Gabrilove, J. Gabrilove, S. Waxman, 2012, Clinical Cancer Research.